Vioxx Cardiovascular Risks Were Evident in 2000

"The results of a cumulative meta-analysis suggest that the cardiovascular adverse effects related to rofecoxib (Vioxx) were evident in 2000, according to a report in The Lancet, to be published online November 5th."